Literature DB >> 24030229

Perforating Crohn's disease: conservative and surgical treatment.

Gianluca M Sampietro1, Silvia Casiraghi, Diego Foschi.   

Abstract

Surgery is a part of the clinical history of patients with Crohn's disease (CD) since nearly all the patients receive at least one surgical procedure. The main indication for surgery is obstruction, but 50-60% of patients present a concomitant perforating disease at surgery, and 10% of patients have a primary indication for abscess or fistula. Generally, fistulas are classified on an anatomical basis, indicating the site of origin followed by the target (i.e. ileocolic, ileovesical, etc.). Enteroenteric fistulas are frequently asymptomatic and are not always considered an indication for surgery. However, in case of bypass with severe malnutrition or bacterial overgrowth (i.e. duodenal involvement), surgery is the only option. Enterovesical, enteroureteral and enterobiliary fistulas, due to their potential for septic complications, are a definite indication for surgery. Enterogenital fistulas have an indication mainly for their impact on the quality of life. Enterocutaneous fistulas are, in most cases, a late surgical complication, and the indication and timing for treatment are due to their output volume. Abscesses may be present alone or in association with enteric fistulas. The initial approach is conservative, and a percutaneous drainage should be a good treatment or a bridge to elective surgery. Since a modern surgical approach to CD has to be minimally invasive and highly conservative whenever possible, the presence of perforating disease should be well characterized in order to plan a laparoscopic approach and to reduce the amount of resected bowel, in case combining resection and strictureplasty. Perforating CD necessitates a multidisciplinary approach involving, behind the gastroenterologist and the surgeon, the radiologist, the urologist, the gynecologist and the nutritionist in order to obtain the best tailored treatment.
© 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2013        PMID: 24030229     DOI: 10.1159/000353373

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  5 in total

Review 1.  Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): Crohn's disease.

Authors:  G Pellino; D S Keller; G M Sampietro; I Angriman; M Carvello; V Celentano; F Colombo; F Di Candido; S Laureti; G Luglio; G Poggioli; M Rottoli; S Scaringi; G Sciaudone; G Sica; L Sofo; S Leone; S Danese; A Spinelli; G Delaini; F Selvaggi
Journal:  Tech Coloproctol       Date:  2020-03-14       Impact factor: 3.781

2.  Enterocutaneous fistula in severely active Crohn's disease: preoperative anti-TNF alpha treatment to limit bowel resection-report of a case.

Authors:  Peter Wilhelm; Andreas Kirschniak; Jonas Johannink; Sascha Kaufmann; Thomas Klag; Jan Wehkamp; Claudius Falch
Journal:  Int J Colorectal Dis       Date:  2018-11-29       Impact factor: 2.571

Review 3.  Surgical Management of Complex Enteric Fistulas in Crohn's Disease.

Authors:  Luiz Felipe de Campos-Lobato; Ravi P Kiran
Journal:  Clin Colon Rectal Surg       Date:  2019-07-02

4.  Magnetic resonance enterographic predictors of one-year outcome in ileal and ileocolonic Crohn's disease treated with anti-tumor necrosis factor antibodies.

Authors:  Piotr Eder; Michal Michalak; Katarzyna Katulska; Liliana Lykowska-Szuber; Iwona Krela-Kazmierczak; Kamila Stawczyk-Eder; Katarzyna Klimczak; Aleksandra Szymczak; Krzysztof Linke
Journal:  Sci Rep       Date:  2015-05-20       Impact factor: 4.379

5.  Successful Non-Operative Treatment of Enterovesical and Enterocutaneous Fistulas Due to Crohn's Disease.

Authors:  Hui Li; Lu Xie; Hongdi Yao; Lexing Zhang; Sanhong Liang; Wen Lyu
Journal:  Int Med Case Rep J       Date:  2022-03-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.